BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38153423)

  • 1. The ability and optimal cutoff value of serum cell division cycle 42 in estimating major adverse cardiac event in STEMI patients treated with percutaneous coronary intervention.
    Luan S; Zhang L; Cheng X; Wang Y; Feng Q; Wei L; Jiang F; Liu J
    Heart Vessels; 2024 Apr; 39(4):277-287. PubMed ID: 38153423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum histone deacetylase 4 longitudinal change for estimating major adverse cardiovascular events in acute coronary syndrome patients receiving percutaneous coronary intervention.
    Xu H; Zhang J; Jia H; Xing F; Cong H
    Ir J Med Sci; 2023 Dec; 192(6):2689-2696. PubMed ID: 36849652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum VCAM-1 and ICAM-1 measurement assists for MACE risk estimation in ST-segment elevation myocardial infarction patients.
    Yu J; Liu Y; Peng W; Xu Z
    J Clin Lab Anal; 2022 Oct; 36(10):e24685. PubMed ID: 36045604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The abnormal level and prognostic potency of multiple inflammatory cytokines in PCI-treated STEMI patients.
    Zhang J; Xu H; Yao M; Jia H; Cong H
    J Clin Lab Anal; 2022 Nov; 36(11):e24730. PubMed ID: 36245413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiography-guided Multivessel Percutaneous Coronary Intervention Versus Ischemia-guided Percutaneous Coronary Intervention Versus Medical Therapy in the Management of Significant Disease in Non-Infarct-related Arteries in ST-Elevation Myocardial Infarction Patients With Multivessel Coronary Disease.
    Perera D; Crake T; Lee V
    Crit Pathw Cardiol; 2018 Jun; 17(2):77-82. PubMed ID: 29768315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-hospital major adverse cardiovascular events after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: a retrospective study under the China chest pain center (standard center) treatment system.
    Huang L; Zhang J; Huang Q; Cui R; Chen J
    BMC Cardiovasc Disord; 2023 Apr; 23(1):198. PubMed ID: 37069503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical utility of circulating cell division control 42 in small-vessel coronary artery disease patients undergoing drug-coated balloon treatment.
    Wu L; Li H; Chen H; Fan C; Lu Y; Wei R; Yang G; Jia Y
    BMC Cardiovasc Disord; 2023 Oct; 23(1):496. PubMed ID: 37805479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Yang L; Dong H; Lu H; Liao Y; Zhang H; Xu L; Tan Y; Cao S; Tan J; Fu S
    Medicine (Baltimore); 2019 Mar; 98(12):e14920. PubMed ID: 30896649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of platelet/lymphocyte ratio and CAMI-STEMI score for major adverse cardiac events in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: A prospective observational study.
    Wang Y; Peng Z
    Medicine (Baltimore); 2021 Aug; 100(33):e26942. PubMed ID: 34414954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year Outcomes in Patients with ST-segment Elevation Myocardial Infarction Caused by Unprotected Left Main Coronary Artery Occlusion Treated by Primary Percutaneous Coronary Intervention.
    Liu HW; Han YL; Jin QM; Wang XZ; Ma YY; Wang G; Wang B; Xu K; Li Y; Chen SL
    Chin Med J (Engl); 2018 Jun; 131(12):1412-1419. PubMed ID: 29893357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study.
    Chen Y; Jiang D; Tao H; Ge P; Duan Q
    BMC Cardiovasc Disord; 2022 Oct; 22(1):434. PubMed ID: 36199038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive values of bilirubin for in-hospital adverse events in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.
    Ying C; Liu CF; Guo DQ; Du ZR; Wei YJ
    Clinics (Sao Paulo); 2023; 78():100306. PubMed ID: 37949037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):E40-E55. PubMed ID: 31423723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of infarct location and size on clinical outcome after ST-elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Reindl M; Holzknecht M; Tiller C; Lechner I; Schiestl M; Simma F; Pamminger M; Henninger B; Mayr A; Klug G; Bauer A; Metzler B; Reinstadler SJ
    Int J Cardiol; 2020 Feb; 301():14-20. PubMed ID: 31761400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention.
    Liu HT; Chen M; Yu J; Li WJ; Tao L; Li Y; Guo WY; Wang HC
    Medicine (Baltimore); 2015 Jan; 94(4):e449. PubMed ID: 25634182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-Related Differences in Short- and Long-Term Outcome among Young and Middle-Aged Patients for ST-Segment Elevation Myocardial Infarction Underwent Percutaneous Coronary Intervention.
    Fu WX; Zhou TN; Wang XZ; Zhang L; Jing QM; Han YL
    Chin Med J (Engl); 2018 Jun; 131(12):1420-1429. PubMed ID: 29893358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum ACSL4 levels in patients with ST-segment elevation myocardial infarction (STEMI) and its association with one-year major adverse cardiovascular events (MACE): A prospective cohort study.
    Hu Y; Li Q; Wang Y
    Medicine (Baltimore); 2024 Jan; 103(2):e36870. PubMed ID: 38215103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk score based on simple angiographic characteristics to aid in choosing the optimal revascularization strategy for patients with multivessel disease presenting with ST-elevation myocardial infarction.
    Schamroth Pravda N; Witberg G; Zusman O; Landes U; Bental T; Assali A; Vaknin Assa H; Greenberg G; Codner P; Perl L; Kornowski R
    Coron Artery Dis; 2020 Nov; 31(7):597-605. PubMed ID: 32271245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of fractalkine/CX3CL1 concentration in patients with acute myocardial infarction treated with primary percutaneous coronary intervention.
    Xu B; Qian Y; Zhao Y; Fang Z; Tang K; Zhou N; Li D; Wang J
    Cytokine; 2019 Jan; 113():365-370. PubMed ID: 30352758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease treated by primary percutaneous coronary intervention: Insights from the ORBI registry.
    Pimor A; Auffret V; Didier R; Delaunay R; Filippi E; Hacot JP; Saouli D; Rouault G; Druelles P; Bot E; Coudert I; Boulanger B; Le Guellec M; Boulmier D; Leurent G; Bedossa M; Gilard M; Le Breton H
    Arch Cardiovasc Dis; 2018 Nov; 111(11):656-665. PubMed ID: 29229216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.